Dr. Rosenzweig Discusses the Standard of Care in Amyloidosis

Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.

Autologous stem cell transplant, the current standard of care, is generally well tolerated by patients who are eligible, says Rosenzweig. For those who are not eligible, Rosenzweig says that a bortezomib (Velcade)-based regimen is often used, which is also generally well tolerated.

The treatment landscape of immunoglobulin light chain (AL) amyloidosis is rapidly expanding with novel systemic therapies such as daratumumab (Darzalex). Daratumumab is very well tolerated, and it is making its way to the frontline setting, says Rosenzweig. Clinical trials are underway exploring daratumumab in combination with bortezomib-based regimens for AL amyloidosis.